Richard S.  Eiswirth, Jr. net worth and biography

Richard Eiswirth, Jr. Biography and Net Worth

Richard S. Eiswirth, Jr. was promoted to President and Chief Executive Officer effective January 2, 2019. Mr. Eiswirth previously served as President and Chief Financial Officer of our Company since January 2016; our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth served as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chaired the audit committee; as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.

What is Richard S. Eiswirth, Jr.'s net worth?

The estimated net worth of Richard S. Eiswirth, Jr. is at least $951,605.80 as of May 7th, 2018. Mr. Eiswirth, Jr. owns 171,770 shares of Alimera Sciences stock worth more than $951,606 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Eiswirth, Jr. may own. Learn More about Richard S. Eiswirth, Jr.'s net worth.

How do I contact Richard S. Eiswirth, Jr.?

The corporate mailing address for Mr. Eiswirth, Jr. and other Alimera Sciences executives is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. Alimera Sciences can also be reached via phone at (678) 990-5740 and via email at [email protected]. Learn More on Richard S. Eiswirth, Jr.'s contact information.

Has Richard S. Eiswirth, Jr. been buying or selling shares of Alimera Sciences?

Richard S. Eiswirth, Jr. has not been actively trading shares of Alimera Sciences during the last ninety days. Most recently, on Wednesday, December 15th, Richard S. Eiswirth, Jr. bought 484 shares of Alimera Sciences stock. The stock was acquired at an average cost of $4.50 per share, with a total value of $2,178.00. Learn More on Richard S. Eiswirth, Jr.'s trading history.

Who are Alimera Sciences' active insiders?

Alimera Sciences' insider roster includes Philip Ashman (COO), Richard Eiswirth, Jr. (CEO), John Jones (CFO), and James Largent (Director). Learn More on Alimera Sciences' active insiders.

Richard S. Eiswirth, Jr. Insider Trading History at Alimera Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2021Buy484$4.50$2,178.00View SEC Filing Icon  
12/2/2021Buy5,000$4.89$24,450.00View SEC Filing Icon  
11/5/2021Buy1,400$5.50$7,700.00View SEC Filing Icon  
11/3/2021Buy28,005$4.45$124,622.25View SEC Filing Icon  
11/14/2019Buy100,000$5.21$521,000.00
5/7/2018Buy10,000$1.05$10,500.00171,770View SEC Filing Icon  
1/19/2018Sell13,410$1.20$16,092.0084,779View SEC Filing Icon  
1/17/2018Sell14,494$1.23$17,827.6298,619View SEC Filing Icon  
9/15/2016Sell51,471$1.51$77,721.2186,445View SEC Filing Icon  
12/16/2015Sell46,669$2.31$107,805.3934,974View SEC Filing Icon  
10/15/2015Sell13,625$2.69$36,651.2534,974View SEC Filing Icon  
3/6/2015Buy10,000$4.84$48,400.00View SEC Filing Icon  
See Full Table

Richard S. Eiswirth, Jr. Buying and Selling Activity at Alimera Sciences

This chart shows Richard S Eiswirth Jr's buying and selling at Alimera Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alimera Sciences Company Overview

Alimera Sciences logo
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $5.54
Low: $5.54
High: $5.54

50 Day Range

MA: $5.55
Low: $5.19
High: $5.60

2 Week Range

Now: $5.54
Low: $2.61
High: $5.65

Volume

N/A

Average Volume

376,318 shs

Market Capitalization

$290.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25